NO20060605L - 2-4-(hydroxymethyl-fenylamino)-piperidin-1-YL!-N-(9H-carbazol-3-YL)-acetamin derivater og beslektede forbindelser som neuropeptid Y5 (NPY5) ligander for behandling av fedme - Google Patents

2-4-(hydroxymethyl-fenylamino)-piperidin-1-YL!-N-(9H-carbazol-3-YL)-acetamin derivater og beslektede forbindelser som neuropeptid Y5 (NPY5) ligander for behandling av fedme

Info

Publication number
NO20060605L
NO20060605L NO20060605A NO20060605A NO20060605L NO 20060605 L NO20060605 L NO 20060605L NO 20060605 A NO20060605 A NO 20060605A NO 20060605 A NO20060605 A NO 20060605A NO 20060605 L NO20060605 L NO 20060605L
Authority
NO
Norway
Prior art keywords
treatment
acetamine
npy5
carbazol
neuropeptide
Prior art date
Application number
NO20060605A
Other languages
English (en)
Inventor
Helmut Heinrich Buschmann
Antoni Torrens Jover
Josep Mas Prio
Alberto Dordal Zueras
Maria Angeles Fisas Escasany
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of NO20060605L publication Critical patent/NO20060605L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Endocrinology (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår 1,4-disubstituerte piperidinforbindelser med den genereUe formelen (I), fremgangsmåter for deres fremstUling, medikamenter omfattende disse forbindelsene så vel som deres anvendelse for fremstillingen av et medikament for behandlingen av mennesker eller dyr.
NO20060605A 2003-07-30 2006-02-07 2-4-(hydroxymethyl-fenylamino)-piperidin-1-YL!-N-(9H-carbazol-3-YL)-acetamin derivater og beslektede forbindelser som neuropeptid Y5 (NPY5) ligander for behandling av fedme NO20060605L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301813A ES2222833B1 (es) 2003-07-30 2003-07-30 Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
PCT/EP2004/008517 WO2005013990A1 (en) 2003-07-30 2004-07-29 2-`4-(hydroxymethyl-phenylamino) -piperidine-1-yl!-n- (9h-carbazol-3-yl) - acetamine derivatives and related compounds as neuropeptide y5 (npy5) ligands for the treatment of obesity

Publications (1)

Publication Number Publication Date
NO20060605L true NO20060605L (no) 2006-02-07

Family

ID=34130546

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20060553A NO20060553L (no) 2003-07-30 2006-02-02 2-4-(fenylamino)-piperidin-1-YL!-N-fenyl-acetamin derivater og beslektede sammensetninger som neuropeptid Y5 (NPY5) ligander for behandling av fedme
NO20060605A NO20060605L (no) 2003-07-30 2006-02-07 2-4-(hydroxymethyl-fenylamino)-piperidin-1-YL!-N-(9H-carbazol-3-YL)-acetamin derivater og beslektede forbindelser som neuropeptid Y5 (NPY5) ligander for behandling av fedme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20060553A NO20060553L (no) 2003-07-30 2006-02-02 2-4-(fenylamino)-piperidin-1-YL!-N-fenyl-acetamin derivater og beslektede sammensetninger som neuropeptid Y5 (NPY5) ligander for behandling av fedme

Country Status (19)

Country Link
US (4) US7888510B2 (no)
EP (2) EP1648458B1 (no)
JP (2) JP2007500162A (no)
CN (2) CN1829516A (no)
AR (1) AR045154A1 (no)
AT (2) ATE348615T1 (no)
AU (2) AU2004262491A1 (no)
BR (2) BRPI0413091A (no)
CA (2) CA2534096A1 (no)
DE (2) DE602004003831T2 (no)
ES (3) ES2222833B1 (no)
MX (2) MXPA06001140A (no)
MY (1) MY136965A (no)
NO (2) NO20060553L (no)
PE (1) PE20050332A1 (no)
PT (2) PT1651220E (no)
RU (2) RU2006105711A (no)
TW (1) TW200510379A (no)
WO (2) WO2005013988A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9560804B1 (en) 2010-12-15 2017-02-07 Marion Calmer Stalk roll with flutes defining a recess
ES2222833B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
EP1918281A1 (en) * 2006-11-02 2008-05-07 Laboratorios del Dr. Esteve S.A. Phenylamino-substituted piperidine compounds, their preparation and use as medicaments
AU2008219115A1 (en) * 2007-02-16 2008-08-28 Synta Pharmaceuticals Corp. Substituted fused-ring compounds for inflammation and immune-related uses
EP2352730A4 (en) * 2008-11-07 2012-04-25 Lundbeck & Co As H BIOLOGICALLY ACTIVE AMIDES
EP4196119A4 (en) * 2020-08-11 2024-07-31 Univ Michigan State PROTEASOME ACTIVATORS AND THEIR USES

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019682A1 (en) 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
AU7692996A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
EP0955293B1 (en) 1996-12-03 2003-03-19 Banyu Pharmaceutical Co., Ltd. Urea derivatives
CA2251368A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
US6048900A (en) * 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
WO1998040356A1 (fr) 1997-03-12 1998-09-17 Banyu Pharmaceutical Co., Ltd. Medicaments contenant des derives d'aminopyridine comme ingredient actif
US7534857B2 (en) * 1997-12-19 2009-05-19 Centegen, Inc. Methods and compositions for the treatment and prevention of staphylococcal infections
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
CN1329589A (zh) 1998-10-07 2002-01-02 奥索-麦克尼尔药品公司 用作神经肽yy5受体的配体的n－芳烷基氨基1,2,3,4－四氢萘
US6399631B1 (en) * 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
ATE306482T1 (de) * 1999-07-28 2005-10-15 Ortho Mcneil Pharm Inc Amine and amide als ligande für den neuropeptid-y y5 rezeptor, und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
EP1206262A4 (en) 1999-08-26 2003-01-02 Bristol Myers Squibb Co Y NEUROPEPTID ANTAGONISTS: SPIROISOQUINOLINONE DERIVATIVES
RS50767B (sr) * 2001-07-24 2010-08-31 Richter Gedeon Vegyeszeti Gyar Rt. Piperidinski derivati kao antagonisti nmda receptora
US7067549B2 (en) * 2001-12-31 2006-06-27 Actelion Pharmaceuticals Ag Pyrrolidone carboxamides
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
ES2222833B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
ES2228267B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.

Also Published As

Publication number Publication date
WO2005013988A1 (en) 2005-02-17
ES2222833B1 (es) 2006-03-01
JP2007500162A (ja) 2007-01-11
US20070105853A1 (en) 2007-05-10
PE20050332A1 (es) 2005-06-12
AU2004262491A1 (en) 2005-02-17
EP1651220A1 (en) 2006-05-03
ES2279419T3 (es) 2007-08-16
JP2007500169A (ja) 2007-01-11
RU2006105792A (ru) 2007-09-20
EP1651220B1 (en) 2006-12-20
BRPI0412860A (pt) 2006-10-03
PT1651220E (pt) 2007-03-30
DE602004003829T2 (de) 2007-09-20
MXPA06001226A (es) 2006-05-15
BRPI0413091A (pt) 2006-10-03
DE602004003829D1 (de) 2007-02-01
ATE348615T1 (de) 2007-01-15
ES2222833A1 (es) 2005-02-01
AR045154A1 (es) 2005-10-19
ES2279400T3 (es) 2007-08-16
NO20060553L (no) 2006-02-02
MY136965A (en) 2008-12-31
EP1648458A1 (en) 2006-04-26
CA2534101A1 (en) 2005-02-17
WO2005013988A8 (en) 2006-11-09
US20100280072A1 (en) 2010-11-04
MXPA06001140A (es) 2006-04-24
CN1832745A (zh) 2006-09-13
US20110172270A1 (en) 2011-07-14
CA2534096A1 (en) 2005-02-17
ATE348614T1 (de) 2007-01-15
RU2006105711A (ru) 2007-09-20
DE602004003831T2 (de) 2007-10-25
CN1829516A (zh) 2006-09-06
AU2004262482A1 (en) 2005-02-17
TW200510379A (en) 2005-03-16
WO2005013990A1 (en) 2005-02-17
EP1648458B1 (en) 2006-12-20
US20080119516A1 (en) 2008-05-22
PT1648458E (pt) 2007-03-30
US7888510B2 (en) 2011-02-15
DE602004003831D1 (de) 2007-02-01

Similar Documents

Publication Publication Date Title
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
NO20063928L (no) Substituerte kinolinforbindelser
NO20062303L (no) Pyrazinderivater og farmasoytisk anvendelse derav
NO20090321L (no) Anvendelse av substituerte 2-aminotyetraliner for produksjon av et medikament for forhindringen, lettingen og/eller behandlingen av diverse typer smerte
NO20052493L (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
NO20045281L (no) Tiazolidinoner og anvendelse derav som polo-lignende kinaseinhibitorer
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
NO20060605L (no) 2-4-(hydroxymethyl-fenylamino)-piperidin-1-YL!-N-(9H-carbazol-3-YL)-acetamin derivater og beslektede forbindelser som neuropeptid Y5 (NPY5) ligander for behandling av fedme
CY1108267T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
NO20052496L (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20054083L (no) Nye sammenkoblede triazoloner og deres anvendelse
MY136034A (en) New medicaments for the treatment of chronic obstructive pulmonary disease
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
HRP20050103A2 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
NO20075158L (no) Nye sykliske aminer
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20060718L (no) Substituerte tiofoner og deres anvendelse
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
NO20040881L (no) Orale antidiabetes midler.
NO20074084L (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikamenter og medikamenter inneholdende disse
ATE349448T1 (de) Pyrazol-3,4-d-pyrimidinderivate und ihre verwendung bei der behandlung von h.pylori- infektionen
RS51858B (en) 4 - [(3-FLUOROPHENOXY) PHENYLMETHYL] PIPERIDINE METANSULPHONATE: ITS USES, PROCESSING METHODS AND PHARMACEUTICAL COMPOSITIONS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application